Skip to main content
main-content
Erschienen in: Der Onkologe 5/2022

07.04.2022 | Thrombose | CME

Gerinnungsstörungen bei Tumorerkrankungen

verfasst von: Dr. med. Minna Voigtländer, Prof. Dr. med. Florian Langer

Erschienen in: Der Onkologe | Ausgabe 5/2022

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Diagnostik und Therapie paraneoplastischer Gerinnungsstörungen stellen im Praxisalltag eine große Herausforderung dar. Während die prophylaktische Antikoagulation zur Vorbeugung einer venösen Thromboembolie (VTE) bei chirurgischen und akut erkrankten internistischen Tumorpatienten etablierter Standard ist, muss unter ambulanter Systemtherapie eine besonders sorgfältige Abwägung auf Basis validierter Risikomodelle erfolgen. Die Differenzialtherapie der krebsassoziierten VTE umfasst niedermolekulare Heparine und direkte orale Faktor-Xa-Inhibitoren. Bei disseminierter intravasaler Gerinnung richten sich die therapeutischen Maßnahmen strikt nach der klinischen Symptomatik. Das erworbene Von-Willebrand-Syndrom kann bei Patienten mit myeloproliferativen Neoplasien oder Plasmazellerkrankungen eine schwere Blutungsneigung hervorrufen. In 15 % der Fälle ist die erworbene Hämophilie A, verursacht durch inhibitorische Autoantikörper gegen Faktor VIII, mit einem Malignom assoziiert.
Literatur
1.
Zurück zum Zitat Langer F (2021) Malignomassoziierte venöse Thromboembolie. In: Klinische Angiologie. Springer, Berlin Heidelberg Langer F (2021) Malignomassoziierte venöse Thromboembolie. In: Klinische Angiologie. Springer, Berlin Heidelberg
2.
Zurück zum Zitat Farge D et al (2019) 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20(10):e566–e581 PubMedCrossRef Farge D et al (2019) 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20(10):e566–e581 PubMedCrossRef
3.
Zurück zum Zitat Key NS et al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38(5):496–520 PubMedCrossRef Key NS et al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38(5):496–520 PubMedCrossRef
4.
Zurück zum Zitat Lyman GH et al (2021) American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5(4):927–974 PubMedPubMedCentralCrossRef Lyman GH et al (2021) American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5(4):927–974 PubMedPubMedCentralCrossRef
5.
6.
Zurück zum Zitat Carrier M et al (2019) Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 380(8):711–719 PubMedCrossRef Carrier M et al (2019) Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 380(8):711–719 PubMedCrossRef
7.
Zurück zum Zitat Khorana AA et al (2019) Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 380(8):720–728 PubMedCrossRef Khorana AA et al (2019) Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 380(8):720–728 PubMedCrossRef
9.
Zurück zum Zitat Tun NM, Guevara E, Oo TH (2016) Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Blood Coagul Fibrinolysis 27(3):270–274 PubMedCrossRef Tun NM, Guevara E, Oo TH (2016) Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Blood Coagul Fibrinolysis 27(3):270–274 PubMedCrossRef
10.
Zurück zum Zitat Fotiou D, Gavriatopoulou M, Terpos E (2020) Multiple myeloma and thrombosis: prophylaxis and risk prediction tools. Cancers 12(1):191 PubMedCentralCrossRef Fotiou D, Gavriatopoulou M, Terpos E (2020) Multiple myeloma and thrombosis: prophylaxis and risk prediction tools. Cancers 12(1):191 PubMedCentralCrossRef
11.
Zurück zum Zitat Agnelli G et al (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 82(17):599–607 Agnelli G et al (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 82(17):599–607
12.
Zurück zum Zitat Young AM et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017–2023 PubMedCrossRef Young AM et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017–2023 PubMedCrossRef
13.
Zurück zum Zitat Raskob GE et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615–624 PubMedCrossRef Raskob GE et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615–624 PubMedCrossRef
14.
Zurück zum Zitat Jara-Palomares L et al (2017) Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study. Thromb Res 157:90–96 PubMedCrossRef Jara-Palomares L et al (2017) Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study. Thromb Res 157:90–96 PubMedCrossRef
15.
Zurück zum Zitat Caiano L et al (2021) Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 19(10):2468–2479 PubMedCrossRef Caiano L et al (2021) Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 19(10):2468–2479 PubMedCrossRef
16.
Zurück zum Zitat Konstantinides SV et al (2020) 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41(4):543–603 PubMedCrossRef Konstantinides SV et al (2020) 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41(4):543–603 PubMedCrossRef
17.
Zurück zum Zitat Stevens SM et al (2021) Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160(6):e545–e608 PubMedCrossRef Stevens SM et al (2021) Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160(6):e545–e608 PubMedCrossRef
18.
Zurück zum Zitat McBane RD 2nd et al (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 18(2):411–421 PubMedCrossRef McBane RD 2nd et al (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 18(2):411–421 PubMedCrossRef
19.
20.
Zurück zum Zitat Bauersachs R et al (2021) Management and outcomes of patients with isolated superficial vein thrombosis under real life conditions (INSIGHTS-SVT). Eur J Vasc Endovasc Surg 62(2):241–249 PubMedCrossRef Bauersachs R et al (2021) Management and outcomes of patients with isolated superficial vein thrombosis under real life conditions (INSIGHTS-SVT). Eur J Vasc Endovasc Surg 62(2):241–249 PubMedCrossRef
21.
Zurück zum Zitat Levi M, Ten HC (1999) Disseminated intravascular coagulation. N Engl J Med 341(8):586–592 PubMedCrossRef Levi M, Ten HC (1999) Disseminated intravascular coagulation. N Engl J Med 341(8):586–592 PubMedCrossRef
22.
Zurück zum Zitat Squizzato A et al (2020) Underlying disorders of disseminated intravascular coagulation: communication from the ISTH SSC subcommittees on disseminated Intravascular coagulation and Perioperative and critical care thrombosis and Hemostasis. J Thromb Haemost 18(9):2400–2407 PubMedCrossRef Squizzato A et al (2020) Underlying disorders of disseminated intravascular coagulation: communication from the ISTH SSC subcommittees on disseminated Intravascular coagulation and Perioperative and critical care thrombosis and Hemostasis. J Thromb Haemost 18(9):2400–2407 PubMedCrossRef
23.
Zurück zum Zitat Wada H, Matsumoto T, Yamashita Y (2014) Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. j intensive care 2(1):15 PubMedPubMedCentralCrossRef Wada H, Matsumoto T, Yamashita Y (2014) Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. j intensive care 2(1):15 PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Levi M (2018) Clinical characteristics of disseminated intravascular coagulation in patients with solid and hematological cancers. Thromb Res 164(Suppl 1):S77–S81 PubMedCrossRef Levi M (2018) Clinical characteristics of disseminated intravascular coagulation in patients with solid and hematological cancers. Thromb Res 164(Suppl 1):S77–S81 PubMedCrossRef
25.
Zurück zum Zitat Taylor FB Jr. et al (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86(5):1327–1330 PubMedCrossRef Taylor FB Jr. et al (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86(5):1327–1330 PubMedCrossRef
26.
Zurück zum Zitat Levi M, Scully M (2018) How I treat disseminated intravascular coagulation. Blood 131(8):845–854 PubMedCrossRef Levi M, Scully M (2018) How I treat disseminated intravascular coagulation. Blood 131(8):845–854 PubMedCrossRef
27.
Zurück zum Zitat Ten Cate H, Leader A (2021) Management of disseminated Intravascular coagulation in acute leukemias. Hamostaseologie 41(2):120–126 PubMedCrossRef Ten Cate H, Leader A (2021) Management of disseminated Intravascular coagulation in acute leukemias. Hamostaseologie 41(2):120–126 PubMedCrossRef
28.
Zurück zum Zitat Squizzato A et al (2016) Supportive management strategies for disseminated intravascular coagulation. An international consensus. Thromb Haemost 115(5):896–904 PubMedCrossRef Squizzato A et al (2016) Supportive management strategies for disseminated intravascular coagulation. An international consensus. Thromb Haemost 115(5):896–904 PubMedCrossRef
29.
Zurück zum Zitat Biswas A et al (2014) Coagulation factor XIII deficiency. Diagnosis, prevalence and management of inherited and acquired forms. Hamostaseologie 34(2):160–166 PubMedCrossRef Biswas A et al (2014) Coagulation factor XIII deficiency. Diagnosis, prevalence and management of inherited and acquired forms. Hamostaseologie 34(2):160–166 PubMedCrossRef
30.
Zurück zum Zitat Iba T et al (2021) Therapeutic strategies in patients with coagulopathy and disseminated intravascular coagulation: awareness of the phase-dependent characteristics. Minerva Med 112(6):701–712 PubMed Iba T et al (2021) Therapeutic strategies in patients with coagulopathy and disseminated intravascular coagulation: awareness of the phase-dependent characteristics. Minerva Med 112(6):701–712 PubMed
31.
Zurück zum Zitat Leebeek FW, Eikenboom JC (2016) Von Willebrand’s Disease. N Engl J Med 375(21):2067–2080 PubMedCrossRef Leebeek FW, Eikenboom JC (2016) Von Willebrand’s Disease. N Engl J Med 375(21):2067–2080 PubMedCrossRef
32.
Zurück zum Zitat Tefferi A, Barbui T (2020) Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 95(12):1599–1613 PubMedCrossRef Tefferi A, Barbui T (2020) Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 95(12):1599–1613 PubMedCrossRef
33.
Zurück zum Zitat van Genderen PJ et al (1996) Acquired von Willebrand disease in myeloproliferative disorders. Leuk Lymphoma 22(Suppl 1):79–82 PubMedCrossRef van Genderen PJ et al (1996) Acquired von Willebrand disease in myeloproliferative disorders. Leuk Lymphoma 22(Suppl 1):79–82 PubMedCrossRef
35.
Zurück zum Zitat Tiede A (2012) Diagnosis and treatment of acquired von Willebrand syndrome. Thromb Res 130(Suppl 2):S2–6 PubMedCrossRef Tiede A (2012) Diagnosis and treatment of acquired von Willebrand syndrome. Thromb Res 130(Suppl 2):S2–6 PubMedCrossRef
36.
Zurück zum Zitat van Genderen PJ et al (1997) Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count. Br J Haematol 99(4):832–836 PubMedCrossRef van Genderen PJ et al (1997) Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count. Br J Haematol 99(4):832–836 PubMedCrossRef
37.
Zurück zum Zitat Tiede A et al (2011) How I treat the acquired von Willebrand syndrome. Blood 117(25):6777–6785 PubMedCrossRef Tiede A et al (2011) How I treat the acquired von Willebrand syndrome. Blood 117(25):6777–6785 PubMedCrossRef
38.
Zurück zum Zitat Michiels JJ et al (2006) Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications. Semin Thromb Hemost 32(6):577–588 PubMedCrossRef Michiels JJ et al (2006) Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications. Semin Thromb Hemost 32(6):577–588 PubMedCrossRef
39.
Zurück zum Zitat Federici AB et al (1998) Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 92(8):2707–2711 PubMedCrossRef Federici AB et al (1998) Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 92(8):2707–2711 PubMedCrossRef
40.
Zurück zum Zitat Dicke C et al (2016) Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias. Ann Hematol 95(6):945–957 PubMedCrossRef Dicke C et al (2016) Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias. Ann Hematol 95(6):945–957 PubMedCrossRef
41.
42.
Zurück zum Zitat Tiede A, Werwitzke S, Scharf RE (2014) Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges. Semin Thromb Hemost 40(7):803–811 PubMedCrossRef Tiede A, Werwitzke S, Scharf RE (2014) Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges. Semin Thromb Hemost 40(7):803–811 PubMedCrossRef
43.
Zurück zum Zitat Tiede A (2021) Critical bleeding in acquired hemophilia A: bypassing agents or recombinant porcine factor VIII? Hamostaseologie 41(4):240–245 PubMedCrossRef Tiede A (2021) Critical bleeding in acquired hemophilia A: bypassing agents or recombinant porcine factor VIII? Hamostaseologie 41(4):240–245 PubMedCrossRef
44.
Zurück zum Zitat Tiede A, Kemkes-Matthes B, Knobl P (2021) Should emicizumab be used in patients with acquired hemophilia A? J Thromb Haemost 19(3):637–644 PubMedCrossRef Tiede A, Kemkes-Matthes B, Knobl P (2021) Should emicizumab be used in patients with acquired hemophilia A? J Thromb Haemost 19(3):637–644 PubMedCrossRef
Metadaten
Titel
Gerinnungsstörungen bei Tumorerkrankungen
verfasst von
Dr. med. Minna Voigtländer
Prof. Dr. med. Florian Langer
Publikationsdatum
07.04.2022
Verlag
Springer Medizin
Erschienen in
Der Onkologe / Ausgabe 5/2022
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-022-01132-9